BAAM
ITCI

Baker Avenue Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Baker Avenue Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-95
Closed -$4.95K – 1563
2023
Q3 		$4.95K Buy
+95
New +$5.54K ﹤0.01% 950

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baker Avenue Asset Management's ITCI Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2023, closing a stake of 95 shares — an estimated $4.95K sold.

Baker Avenue Asset Management first reported a position in ITCI in Q3 2023 and held it in 1 quarter. The position peaked at $4.95K in Q3 2023. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 95 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $4.95K.
  • Baker Avenue Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Intra-Cellular Therapies Inc. position peaked at $4.95K in Q3 2023.
  • 333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.